Medtronic To Promote Amgen’s Osteoporosis Drug
This article was originally published in The Gray Sheet
Executive Summary
Under a three-year strategic partnership with Amgen, Medtronic will start promoting Amgen Inc.’s Prolia (denuosumab) to U.S. spine specialists by July 31. Prolia is FDA-approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture.